On 17 September 2026, U.S. regulators approved the first treatment for pediatric patients with one specific enzyme-missing rare brain disease. Until that day, care for that disease was limited to managing symptoms.

“First approved treatment” means a regulatory first for this disease. It does not mean every eligible child is already treated. It does not mean all rare brain diseases suddenly have a one-shot gene therapy. It does not mean approval equals a personal cure.

Trial evidence for the studied window showed treated patients maintained or improved cognitive scores compared with an untreated historical control group (regulator summary). Company reports also describe a large cognitive score separation in a small treated group versus natural history — treat those company numbers as company-reported.

News about a capability class is not a brand you must invent.